- Disease: Respiratory syncytial virus infection
- Study type: Observational Cohort Study, Prevention
- Study type descriptors: Prospective, Single centre
- Objective: To evaluate the acceptance and safety of the treatment of newborns with nirsevimab during the first season of implementation
- Number of participants enrolled: 477
- Study enrolling from to
- Study includes follow-up for 30 days
Study Data
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to